Abstract

We acknowledge the funding support from the Government of the Republic of Uganda through the Makerere University Research and Innovations Fund (Mak-RIF).

Rights

Copyright © The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Cite as

Kirenga, B., Mugenyi, L., Sánchez-Rico, M., Kyobe, H., Muttamba, W., Mugume, R., Mwesigwa, E., Kalimo, E., Nyombi, V., Segawa, I., Namakula, L., Sekibira, R., Kabweru, W., Byanyima, R., Aanyu-Tukamuhebwa, H., Byakika-Kibwika, P., Mwebesa, H., Hoertel, N. & Bazeyo, W. 2023, 'Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda : a prospective interventional open-label cohort study', Molecular Psychiatry. https://doi.org/10.1038/s41380-023-02004-3

Downloadable citations

Download HTML citationHTML Download BIB citationBIB Download RIS citationRIS
Last updated: 03 May 2024
Was this page helpful?